EFFICACY AND TOLERABILITY OF
RISPERIDONE IN THE TREATMENT OF
DEPRESSIVE DISORDERS.
DANIELA IONESCU1*, CRISTINA DEHELEAN1, SIMONA FUNARTIMOFEI2,
SIMONA DRAGAN3, ELENA GALCA4
1Department of Toxicology, Faculty of Pharmacy, University of Medicine
and Pharmacy “Victor Babes” Timisoara, 2 Murgu E, 300041, Romania
2Institute of Chemistry, Romanian Academy
3Rehabilitation Department, Institute of Cardiology Timisoara,
Romania
4Psychiatry Department, Municipal Hospital Timisoara
*corresponding author: daniela_ionescu2002@yahoo.com
Download Full Article

Abstract:

The aim of this paper was to assess the efficacy and the tolerability of the therapy with risperidone in the case of depressive disorders. 84 adult subjects aged 18-65 years were randomized into two groups: 42 patients into lot A treated with risperidone (1- 2mg/day) and 42 subjects lot B, placebo.
Symptoms were measured using the 17-item Hamilton Rating Scale for Depression (HRSD-17). Other outcomes were the response to therapy, and the adverse events. Mean HRSD-17 scores improved more in the risperidone group than in the placebo group. Headache (19.04% of risperidone group vs. 26.19% of placebo group), somnolence (16.67% vs. 4.76%), dry mouth (9.52% vs. 7.14%), nausea (4.76% vs.11.91%) and weight gain (14.28% vs. 7.14%) were the most frequently reported adverse events. Risperidone produced significant reduction in depression symptoms having a good tolerability.

Top